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Received 9 January 2012; received in revised form 19 January 2012; accepted 20 January 2012Until recently, lamotrigine was approved for the prevention
of bipolar depression. Concomitant administration of lamo-
trigine with mood stabilizer such as valproic acid in patients
with bipolar disorder is gradually becoming popular.1 Here,
we present a case where low-dose lamotrigine was used for
bipolar depression.Whenvalproic acidwasadded for themild
irritability, severe skin rash and fever developed rapidly. Mrs
L, a 45-year-old female, was admitted to acute psychiatric
ward with the diagnosis of bipolar depression. She suffered
from severe sleep disturbance, loss of appetite, loss of
interest, agitation, and suicidal ideations for 1e2 weeks.
Initially, she was administered venlafaxine 75 mg/d, which
gradually increased to 150 mg/d day within 7 days after
admission. During the second week of admission, lamotrigine
25mg/dwasadministered concomitantly to control themood
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doi:10.1016/j.jfma.2012.01.01250mg/dwithin1week. Sincehermoodbecamedysphoric and
irritable within fourth week, low-dose valproic acid 200 mg/
night was administered. After 4 hours of administration of
valproicacid, skin rashandpruritus symptomsoverabdominal
region developed rapidly. These symptoms were quickly
relieved by intramuscular injection of chlorpheniramine
5 mg. and discontinuation of valproic acid. Low-grade fever
with chills developed in the next morning together with
multiple light pinkish rashes spreading over the body. Fever
spiked up to 38.9C, with more prominent skin rash 1 day
later. She suffered from a persistent fever of 38Cwith chills;
diclofenac 25 mg three times a day was prescribed. Subse-
quently, a single oral blister lesion appeared and triamcino-
lone oral gel was given for the lesion. Dermatologists
suggested that betamethasone cream topically should be
continued, and fexofenadine 60 mg and doxepin 25 mg twice
a day were recommended. Pruritus of the body improved
greatly, but the palms and the soles were still itching. She
gradually recovered in 1 week. It is well known that antiepi-
leptic medication lamotriginemay induce skin reaction2 such
as symmetric polymorphic targeted lesions on extremities
and palmoplantar surfaces, with mild lesions on the mucosal
membrane. It usually occurs within a few days of drug
administration and has been suggested to be related to the& Formosan Medical Association. All rights reserved.
196 Y.-C. Chou et al.cascade of clinical dosage.3 A previous study reported that
valproic acid can inhibit eliminationof lamotrigine, leading to
increased risk of lamotrigine-induced skin rash.4 The most
likely explanation is that valproic acid inhibits N-glucur-
onidation (UGT1A4)metabolic pathway of lamotrigine,which
leads to an increase in the concentration of glucuronate form
of lamotrigine by 30e50%, suggesting a 50% dose reduction in
lamotrigine when coadministered with valproic acid.5 Most
clinicians probably have known the risk of monotherapy with
lamotrigine.However, in thetreatmentofbipolardepression,
it is common to use lamotrigine first, with valproic acid
being added later for the mood swing. This case report
suggests that additional attention is required when valproic
acid is added to a patient who has already been treated with
lamotrigine.References
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